Market Overview

Titan Spine Appoints Peter Wehrly to Board of Directors

Share:

Highly Respected Industry Veteran to Provide Expertise and Counsel

Titan Spine, Inc., a medical device surface technology company focused
on developing innovative spinal interbody fusion implants, today
announced the appointment of Peter Wehrly to its Board of Directors. Mr.
Wehrly's appointment, effective July 9, 2018, provides the Company with
extensive medtech market knowledge and experience as it continues to
drive improved patient outcomes1 through the deployment of
its nanoLOCK® surface technology.

nanoLOCK® is the company's next-generation surface technology
featuring enhanced micro and nano-scaled architecture, proven to
significantly improve the osteogenic response it creates.2

Mr. Wehrly commented, "Titan Spine has done a remarkable job forging the
surface technology category in spine over the past several years and has
the opportunity to continue its leadership position with the company's
unique nanoLOCK® offering. I see a clear opportunity for the
Company to further carve out a substantial share of the orthopedic
market and look forward to contributing to Titan Spine's growth and
success."

Mr. Wehrly is currently CEO of Synaptive Medical, a privately-held,
Toronto-based company that combines proprietary surgical planning and
robotic navigation platforms targeted initially for cranial and spinal
applications. Prior to his appointment as CEO of Synaptive in October
2017, Mr. Wehrly was Chairman of the Board of Directors and an advisor
to Synaptive from 2015 to 2017. From April 2016 to August 2017, Mr.
Wehrly served as the CEO of PQ Bypass, a company based in Sunnyvale,
California focused on breakthrough technology for the treatment of
peripheral arterial disease. Previously, he was the Group President of
Developed Markets at Covidien, a medical device manufacturer with annual
sales of over $10.7 billion that was acquired by Medtronic, Inc. in
2015. In this position, Peter held profit and loss responsibility for
the marketing and sale of products to all developed markets outside the
U.S. between 2013 and 2015. Preceding this role, Peter was the Group
President of Respiratory and Monitoring Solutions, Vascular Therapies,
and for all of Covidien's Japanese, Australian-New Zealand, and Canadian
businesses. Prior to Covidien, Mr. Wehrly held the position of President
and CEO at Medingo Youqneam, an Israel-based team that developed a novel
insulin pump for diabetic patients. He also presided over Medtronic's
Spinal, Biologics, and Navigation businesses from 2004 to 2008. Peter
started his career with DePuy, a Johnson & Johnson company.

Peter Ullrich, MD, Chief Executive Officer of Titan Spine, stated, "We
recognize the importance of adding exceptional talent, guidance and
expertise to our Board to help us continue driving Titan's growth. Peter
is a strategic leader who consistently delivers top-line growth and
operational efficiencies across a wide range of global cultures. He has
excelled in both public and private organizations, in both start-ups and
multi-billion-dollar businesses, and in both developed and emerging
markets. We are confident that Peter's addition will advance our near
and long-term goals for further building Titan Spine as the leader in
surface technology medical devices."

Titan Spine offers a full line of Endoskeleton® titanium
implants that feature its proprietary nanoLOCK® surface
technology, which was launched in October 2016 following FDA clearance
in late 2014. The nanoLOCK® surface technology consists of a
unique combination of roughened topographies at the macro, micro, and
nano levels (MMN™). This unique combination of surface topographies is
designed to create an optimal host-bone response and actively
participate in the fusion process by promoting the upregulation of
osteogenic and angiogenic factors necessary for bone growth, encouraging
natural production of bone morphogenetic proteins (BMPs), downregulating
inflammatory factors, and creating the potential for a faster and more
robust fusion.2,3,4 All Endoskeleton® devices are
covered by the company's risk share warranty.

About Titan Spine

Titan Spine, Inc. is a surface technology company focused on the design
and manufacture of interbody fusion devices for the spine. The company
is committed to advancing the science of surface engineering to enhance
the treatment of various pathologies of the spine that require fusion.
Titan Spine, headquartered in Mequon, Wisconsin, markets a full line of
Endoskeleton® interbody devices featuring its proprietary
textured surface in the U.S., Europe, and Australia through its sales
force and a network of independent distributors. To learn more, visit www.titanspine.com.

1 Data on file.

2 Olivares-Navarrete, R., Hyzy S.L., Gittens, R.A., Berg,
M.E., Schneider, J.M., Hotchkiss, K., Schwartz, Z., Boyan, B. D.
Osteoblast lineage cells can discriminate microscale topographic
features on titanium-aluminum-vanadium surfaces. Ann Biomed Eng.
2014 Dec; 42 (12): 2551-61.

3 Olivares-Navarrete, R., Hyzy, S.L., Slosar, P.J.,
Schneider, J.M., Schwartz, Z., and Boyan, B.D. (2015). Implant materials
generate different peri-implant inflammatory factors: PEEK promotes
fibrosis and micro-textured titanium promotes osteogenic factors. Spine,
Volume 40, Issue 6, 399–404.

4 Matteson JL, Greenspan DC, Tighe TB, et al. Assessing the
hierarchical structure of titanium implant surfaces. Journal of
Biomedical Materials Research Part B Applied Biomaterials 104(6). May
2015. DOI:10.1002/jbm.b.33462.

View Comments and Join the Discussion!